Why Zymeworks Stock Is Back in Focus After Q4 Updates

Zymeworks (ZYME) is back on many investors’ watchlists after its Q4 earnings call highlighted progress for lead therapy zanidatumab, fresh regulatory milestones, and a sizable nondilutive funding deal with Royalty Pharma.

The recent Q4 update, stronger balance sheet after the Royalty Pharma deal, and ongoing analyst optimism appear to be feeding into Zymeworks’ recent momentum, with a 7 day share price return of 4.03% and a one year total shareholder return of 118.47% suggesting interest has picked up after earlier weakness.

If this Zymeworks rally has you looking beyond a single name, it could be a good time to scan for other high potential healthcare names using our 32 healthcare AI stocks as a starting point.

With Zymeworks posting a one year total return above 100%, trading at a sizeable discount to the average analyst price target, and tightening its losses, you have to ask: is there still upside here, or has the market already priced in future growth?

Most Popular Narrative: 33.5% Undervalued

The most followed valuation narrative puts Zymeworks’ fair value at $36.46 versus a last close of $24.25, framing the recent rally as only part of the story.

The analysts have a consensus price target of $21.05 for Zymeworks based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $30.0, and the most bearish reporting a price target of just $12.0.

Curious why a fair value above $30 sits alongside such a wide spread of analyst targets? Revenue ramps, margin shifts and a punchy future earnings multiple sit at the heart of this narrative, and the full story joins those moving parts into one valuation roadmap.

Result: Fair Value of $36.46 (UNDERVALUED)

However, this hinges on partners hitting regulatory milestones and delivering Ziihera sales, while any setback in early stage assets could quickly challenge that upside story.

Another View: Price To Sales Paints A Different Picture

While the narrative and our model-based fair value suggest Zymeworks is 33.5% undervalued, the P/S ratio tells a more cautious story. ZYME trades at 16.9x sales versus a fair ratio of 1.7x, the US Biotechs average of 12x, and peer average of 39.1x. That kind of gap can signal valuation risk as much as opportunity, so which lens do you trust more?

Next Steps

If this mix of optimism and caution has you unsure, review the figures yourself soon and decide where you stand, starting with 3 key rewards.

Looking for more investment ideas?

If Zymeworks has sharpened your focus on opportunities, do not stop here, the wider market still holds plenty of ideas that might suit your investing style.

• Target higher potential value by scanning our 46 high quality undervalued stocks and see which companies currently trade below their estimated worth on key fundamentals.
• Prioritise resilience by checking companies in the 63 resilient stocks with low risk scores that pair lower risk scores with business models built to handle different conditions.
• Hunt for future standouts using our screener containing 23 high quality undiscovered gems, where smaller names with solid numbers might be waiting before wider attention arrives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.